AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Ignalis-M 50/1000 Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (1000mg)

Overview Ignalis-M 50/1000 Tablet ER

Duo-Met 50/1000 Extended-Release tablets combine two medications to manage elevated blood glucose in type 2 diabetes patients. This dual action helps prevent serious diabetic complications like renal impairment and vision loss, potentially lowering the risk of cardiovascular events. Duo-Met 50/1000 ER may be used alone or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health status, glucose levels, and other medications. Consuming it with food minimizes stomach upset. Consistent daily dosing, at the same time, maximizes effectiveness; discontinue only under your physician's guidance. Adherence to your prescribed diet and exercise plan is crucial for effective diabetes management; lifestyle significantly impacts glucose control. Common side effects include diarrhea, nausea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is a potential side effect, especially when combined with insulin or sulfonylureas; learn to recognize and manage this complication. This medication isn't suitable for all individuals. Inform your doctor of any pre-existing kidney, liver, heart, or pancreatic conditions, or significant alcohol consumption before starting treatment. Pregnant or lactating women should seek medical advice. Interactions with other medications are possible; disclose all medications to ensure safety. Alcohol should be limited due to its hypoglycemic effect. Your physician will monitor your renal function and blood glucose throughout treatment.

Uses of Ignalis-M 50/1000 Tablet ER

Managing type 2 diabetes

Major Benefits of Ignalis-M 50/1000 Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing it. It's recommended to take Ignalis-M 50/1000 Extended-Release tablets with food.

Common Side effects of Ignalis-M 50/1000 Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Ignalis-M 50/1000 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet; do not crush, chew, or divide it. The Ignalis-M 50/1000 Extended-Release tablet should be taken with a meal.

How Ignalis-M 50/1000 Tablet ER works:

Ignalis-M 50/1000 Extended-Release tablets combine sitagliptin and metformin to manage blood glucose levels. Sitagliptin boosts insulin production by the pancreas, improves insulin utilization, and lessens hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol while taking Ignalis-M 50/1000 Tablet ER is contraindicated.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Ignalis-M 50/1000 tablet might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Ignalis-M 50/1000 tablets are likely unsafe for breastfeeding mothers. Available human data indicates potential drug transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood glucose levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should exercise caution when using Ignalis-M 50/1000 Extended-Release tablets, as dosage modification may be necessary. Individuals with severe kidney disease should avoid this medication. Close monitoring of kidney function is recommended during treatment. Physician consultation is advised.

LiverLiverUNSAFE

Extended-release Ignalis-M 50/1000 tablets pose a likely risk for individuals with hepatic impairment and should be avoided. Medical advice is recommended.

What if you forget to take Ignalis-M 50/1000 Tablet ER :

Should you forget to take your Ignalis-M 50/1000 Extended-Release tablet, administer it immediately upon remembering. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Never take more than the prescribed amount at one time.

Facts to Know About Ignalis-M 50/1000 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Ignalis-M 50/1000 Tablet ER

Ignalis-M 50/1000 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged Ignalis-M 50/1000 Tablet ER use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Ignalis-M 50/1000 Tablet ER may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50/1000 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50/1000 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Lactic acidosis, a serious medical emergency resulting from excess blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Ignalis-M 50/1000 Tablet ER. This rare complication is particularly concerning for patients with kidney disease, the elderly, or those who consume significant amounts of alcohol, and should be avoided in these groups. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these symptoms, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Ignalis-M 50/1000 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Ignalis-M 50/1000 Tablet ER may cause common side effects including hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50/1000 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50/1000 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Ignalis-M 50/1000 Tablet ER. This rare complication is more likely in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience any of these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Ignalis-M 50/1000 Tablet ER use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and ataxia), urinary issues, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Ignalis-M 50/1000 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This combination is not suitable for individuals under 18.
Ignalis-M 50/1000 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50/1000 Tablet ER components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Ignalis-M 50/1000 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency (also known as MALA, or Metformin-associated lactic acidosis), is a potential side effect of Ignalis-M 50/1000 Tablet ER. This condition, caused by excessive blood lactic acid, is rare but more likely in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Ignalis-M 50/1000 Tablet ER use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may cause anemia, neurological issues (including numbness, tingling in extremities, weakness, and ataxia), urinary problems, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Ignalis-M 50/1000 Tablet ...
99
MRP 115
13% off